enGene Therapeutics Inc. SEC filings ENGNW

enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.

Form Description Filed Period
ARS Annual report to shareholders May 8, 2026 Oct 31, 2025
10-K/A Amended annual report Feb 19, 2026 Oct 31, 2025
10-K Annual report Dec 22, 2025 Oct 31, 2025
ARS Annual report to shareholders May 9, 2025 Oct 31, 2024
10-K/A Amended annual report Feb 20, 2025 Oct 31, 2024
10-K Annual report Dec 19, 2024 Oct 31, 2024
ARS Annual report to shareholders Apr 18, 2024 Oct 31, 2023
10-K Annual report Jan 29, 2024 Oct 31, 2023

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ENGN (Nasdaq), ENGNW (Nasdaq)
Fiscal year ends
October 31
Incorporated in
Canada (Federal Level)
Headquarters
Saint-Laurent
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1980845
Former names
enGene Holdings Inc. (until Mar 9, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.